Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (95)	8/24/2000 12:41:51 PM
From: nigel bates	Read Replies (1) \| Respond to of 539

... "Phylos has developed a unique target identification platform for studying complex disease pathways. At the core of this approach are proprietary PROfusion™ libraries constructed from primary cells and tissues that allow the Company to analyze protein:protein, enzyme:substrate, and drug:protein interactions. Phylos’ strategy addresses several inherent limitations of yeast two-hybrid systems, while providing key advantages in functional proteomics. By applying this technology to complex pathway analysis, Phylos has identified potential drug targets for apoptosis and cancer. The Company is currently expanding its internal efforts while seeking partners for additional disease pathways. The Advantages of Applying PROfusion™ Technology The use of the PROfusion™ technology for the identification of protein:protein interactions is an attractive alternative to traditional yeast two-hybrid systems because: * It can utilize proteins derived from any source of RNA - human, microbial, plant, etc. - and the technology can potentially express functional domains of membrane-bound proteins and receptors. * It does not require an in vivo transformation step during library construction, thereby allowing for a much more complete representation of the cellular components encoded by the starting mRNA population. This is an important advantage when one is looking for natural ligands of proteins and drugs. * The composition of the selected pools can be readily monitored through the use of commercially available DNA filters. Combining this analysis with sequencing ensures that the selected pools are thoroughly analyzed. Comprehensive Domain Libraries Phylos has constructed cDNA-derived domain libraries for human bone marrow, kidney, brain, and lung cells, and new libraries are under construction, both for the Company’s internal programs and for its collaborations with partners. For example, Phylos has applied the PROfusion™ technology to the identification of novel binding partners present in an anti-apoptotic pathway. Starting with a pool of uniquely tagged libraries from different tissues, an iterative selection was performed to identify protein:protein interacting pairs. Analysis of the selected domains revealed the enrichment of three members of a protein family known to interact with the primary protein target. In addition, a number of proteins not previously demonstrated to interact with this protein, but known to be involved in the apoptotic pathway, were identified. Each novel interacting protein identified in this way represents a potential target for therapeutic intervention. Ongoing research in this area is focused on the automation of the platform and on further integration with target validation approaches. "